Certified Registered Nurse Anesthetist Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Christine Klein

Nurse Anesthetist, Certified Registered Bingham Farms, MI Certified Registered Nurse Anesthetist

NPI 1831156884 CMS profile 1212591

30200 Telegraph Rd, Suite 220, Bingham Farms, MI 48025

Open in the dashboard

General payments

$1,283

69 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christine Klein of Bingham Farms, MI is reported in the CMS Open Payments database as having received $1,283 across 69 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Anesthetist, Certified Registered profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $380 22
2024 General $732 38
2023 General $171 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christine Klein
  • Nurse Anesthetist, Certified Registered median
  • Middle half of Nurse Anesthetist, Certified Registered
  • National median

In program year 2025, general payments to Christine Klein were reported at $380. Among 25,681 Nurse Anesthetist, Certified Registered profiles paid that year, the median was $46 and the middle half received between $23 and $106.

Show as a table
Year Christine Klein Nurse Anesthetist, Certified Registered median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $34 $17–$77 $132
2022 $0 $35 $19–$82 $149
2023 $171 $38 $20–$90 $160
2024 $732 $42 $22–$96 $164
2025 $380 $46 $23–$106 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $271 13 payments
  2. QOL Medical, LLC $266 11 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $241 15 payments
  4. AbbVie, Inc. $223 15 payments
  5. Lilly USA, LLC $61 3 payments
  6. Merck Sharp & Dohme Corporation $57 4 payments
  7. Regeneron Healthcare Solutions, Inc. $48 2 payments
  8. Janssen Biotech, Inc. $47 3 payments
  9. Ferring Pharmaceuticals Inc. $33 1 payment
  10. Organon LLC $19 1 payment
  11. Other $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,283 69 payments
Products named General payments · program years 2023–2025
  1. Sucraid $244 10 payments
  2. XIFAXAN $209 12 payments
  3. SKYRIZI $205 14 payments
  4. RINVOQ $195 14 payments
  5. ENTYVIO $116 7 payments
  6. EOHILIA $104 4 payments
  7. OMVOH $61 3 payments
  8. DIFICID $57 4 payments
  9. GATTEX $51 2 payments
  10. DUPIXENT $48 2 payments
  11. Other $270 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$43,658

Medicare's payments for the services billed

Medicare patients

391

Average age 72

Services billed

408

206 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 48%
Ischemic heart disease 32%
Diabetes 26%
Depression 18%
Chronic kidney disease 17%
Atrial fibrillation 15%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
  • QOL Medical, LLC $225
$225 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $152
$152 — —
EOHILIA
  • Takeda Pharmaceuticals U.S.A., Inc. $78
$78 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $62
$62 — —
DIFICID
  • Merck Sharp & Dohme Corporation $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record